Comparison of Continuous Versus Intermittent Administration of Triptorelin on the Final Height of Girls with Idiopathic Precocious Puberty

Authors Information
Article Notes and Dates
To Cite : Karamizadeh Z, Rasekhi A R, Kashef S, Saki F, Ashkani-Esfahani S. et al. Comparison of Continuous Versus Intermittent Administration of Triptorelin on the Final Height of Girls with Idiopathic Precocious Puberty, Iran J Pediatr. 2017 ;27(3):e7495. doi: 10.5812/ijp.7495.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Karamizadeh Z, Kashef MA, Jalaeian H, Namazee N. Combined use of growth hormone and gonadotropin-releasing hormone analogue in short normal adolescent girls: a survey from Iran. Kaohsiung J Med Sci. 2006; 22(4): 161-5[DOI][PubMed]
  • 2. Karamizadeh Z, Rasekhi AR. Gray hair in children on triptorelin treatment. Int J Dermatol. 2008; 47(6): 601-4[DOI][PubMed]
  • 3. Crowley WJ, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GJ. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981; 52(2): 370-2[DOI][PubMed]
  • 4. Lahlou N. [Pharmacokinetics and pharmacodynamics of triptorelin]. Ann Urol (Paris). 2005; 39 Suppl 3-84[PubMed]
  • 5. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013; 98(6): 2198-207[DOI][PubMed]
  • 6. Kreiter M, Burstein S, Rosenfield RL, Moll GJ, Cara JF, Yousefzadeh DK, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr. 1990; 117(3): 364-70[PubMed]
  • 7. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf). 2002; 56(2): 129-48[PubMed]
  • 8. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GJ. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001; 86(10): 4711-6[DOI][PubMed]
  • 9. Stewart L, Steinbok P, Daaboul J. Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty. Report of six cases. J Neurosurg. 1998; 88(2): 340-5[DOI][PubMed]
  • 10. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 2008; 10(4): 525-34[DOI][PubMed]
  • 11. Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli GI. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin. Horm Res Paediatr. 2015; 84(6): 396-400[DOI][PubMed]
  • 12. Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, et al. Central precocious puberty: treatment with triptorelin 11.25 mg. ScientificWorldJournal. 2012; 2012: 583751[DOI][PubMed]
  • 13. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007; 92(5): 1697-704[DOI][PubMed]
  • 14. Rahhal S, Clarke WL, Kletter GB. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol. 2009; 1: 1[DOI]
  • 15. Continual suppresion by the histrelin implant for the treatment of central precocious puberty when left in place for two years. Pediatric Academic Societies Meeting.
  • 16. Kletter GB. How should we diagnose and monitor central precocious puberty? J Pediatr Endocrinol Metab. 2008; 21(12): 1105-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Iranian Journal of Pediatrics accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check